Why Celanese, Axon, and Palantir Plunged
Celanese (CE) lost 21.46% of its value on Wednesday after posting fourth-quarter results the day before. The firm posted a revenue decline of 7.8% Y/Y, to $2.37 billion.Celanese is near a decade low after posting a loss and issuing weak guidance. Losses topped $1.91 billion in Q4, compared to a $701 million profit the year before. The automotive and industrial sectors are headwinds, as they cut their inventory.Axon Enterprise (AXON) shares fell by $116.59 to close at $593.42, down by 16.4%. Unfortunately, Northcoast Research’s downgrade hurt AXON stock. The analyst depended on valuation as the bearish thesis. In addition, the analyst believes that Axon will not issue strong guidance for 2025.Axon does not have any competitors that will erode its profit margins. The stock trades at a premium to reflect its strong prospects ahead. Investors may take advantage of the dip in the share price, betting on a rebound after it posts quarterly results.Palantir (PLTR) stock finally lost momentum after shares climbed nearly non-stop for the last six months. PLTR stock dropped by 10.08% on Wednesday. The firm announced a multi-year strategic partnership with SAUR. It will supply contract management processes through Palantir Foundry. This product offers generative AI capabilities. PLTR stock fell when Defense Secretary Pete Hegseth wrote a memo to cut the defense budget by 8% in each of the next five years.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


